The outcome of a cancer treatment should be adapted according to the treatment the patient is receiving and, in some instances, to the tumour type.

The different evaluation systems (RECIST 1.1, iRECIST, mRECIST, EORTC and PERCIST) have all their specific indications and rules, and they should be known by the radiologist and the oncologist.

This review focuses on the criteria to consider cancer as progressive, in relation to cancer treatment and tumour type.

(BELG J MED ONCOL 2022;16(1):29–32)